Background: Visceral hypersensitivity has been shown to be present in irritable bowel syndrome (IBS). This study sought to investigate rectal sensitivity and abdominal symptoms in IBS patients before and after 220 ml cold water intake.
Methods: A total of 60 IBS patients and 18 healthy controls participated in this study. Both the perception thresholds and defecation thresholds to rectal balloon distension were measured. Then, all subjects were asked to drink 220 ml 37 degrees C warm water or 4 degrees C cold water, and these steps were repeated 20 min later. Symptoms including abdominal pain/discomfort, bloating, and diarrhea were recorded during the study.
Results: Compared with the controls, the thresholds of initial sensation to rectal balloon distention in IBS patients were significantly lower while the defecation thresholds were higher in constipation-predominant IBS patients. After drinking cold water, the perception thresholds in IBS patients and the defecation thresholds in diarrhea-predominant IBS patients were further decreased. However, warm water intake did not change the perception thresholds significantly in either IBS patients or controls. A negative linear correlation was found between the symptoms and the visceral perception thresholds in diarrhea-predominant IBS patients who showed significant symptoms after cold water intake.
Conclusion: The results indicated that cold water intake leads to lowered visceral perception thresholds in IBS patients that were inversely relevant to the abdominal symptoms in symptomatic diarrhea-predominant IBS patients. The alteration of rectal sensitivity and abdominal symptoms following cold water stimulation provided further objective evidence for visceral hypersensitivity in IBS patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00535-005-1766-x | DOI Listing |
J Family Med Prim Care
November 2024
Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Background: Despite its prevalence, limited research has explored the direct correlation between irritable bowel syndrome (IBS) and endometriosis, particularly in regions like Saudi Arabia. This study aimed to bridge this gap by investigating the prevalence of IBS among endometriosis patients and identifying associated risk factors.
Materials And Methods: The study conducted a cross-sectional analysis, it was done at King Abdulaziz University Hospital, Jeddah.
Cureus
December 2024
Family and Community Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Introduction Irritable bowel syndrome (IBS) is one of the most prevalent GI conditions, characterized by symptoms such as abdominal pain relieved by defecation, changes in bowel habits (e.g., diarrhea, constipation, or both), and bloating.
View Article and Find Full Text PDFInt J Telemed Appl
December 2024
Abdominal Radiology Unit, Department of Radiology, Hospital Universitario Virgen de las Nieves 18014, Granada, Spain.
Telerobotic ultrasound has emerged as a promising technology in medicine, especially in settings with limited medical access or a lack of specialized personnel. However, there are very few studies evaluating its usefulness in real-world clinical practice. This study evaluates the usefulness of abdominopelvic telerobotic ultrasound in a real-world practice setting.
View Article and Find Full Text PDFBMC Womens Health
December 2024
Department of Basic Sciences - Physiology Division, Ponce Health Sciences University, Ponce Research Institute, PO Box 7004, Ponce, 00732-7004, PR, Puerto Rico.
Background: Endometriosis is a complex gynecological disorder characterized by the ectopic growth of endometrial tissue. Symptoms of endometriosis are known to impair the quality of life of patients, and among these are found dysmenorrhea, chronic pelvic pain, and gastrointestinal (GI) issues. GI issues such as painful bowel movements, bloating and constipation or diarrhea, are one of the common reasons for misdiagnosis with irritable bowel syndrome (IBS).
View Article and Find Full Text PDFIntroduction: Tenapanor is a first-in-class, minimally absorbed intestinal sodium/hydrogen exchanger isoform 3 inhibitor approved by the U.S. Food and Drug Administration for adults with irritable bowel syndrome with constipation (IBS-C).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!